Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
Table 3
Clinicopathologic correlation of HER-2.
Sl no.
Attribute
HER-2 positive (n = 19)
HER-2 negative (n = 245)
valuea overall
valuea PTC
valuea FTC
valuea PDTC
1.
Age in years (mean ± SD)
46.5 ± 15.9
46.3 ± 15.5
0.945
0.131
0.173
—
2.
Gender (M : F)
9 : 10
81 : 164
0.217
0.285
0.562
—
3.
Presence of PDAb, n (%)
3 (15.8)
87 (41.6)
0.762
0.514
0.261
—
4.
Tumor size in cm (mean ± SD)
4.9 ± 3.1
4.7 ± 2.8
0.027
1.000
0.014
—
5.
Multicentricity, n (%)
6 (31.6)
64 (26.8)
0.603
1.000
1.000
—
6.
Extrathyroidal extension, n (%)
7 (36.8)
58 (24.1)
0.269
0.358
0.266
—
7.
Lymph node metastases, n (%)
9 (47.4)
93 (38.1)
0.468
0.411
0.290
—
8.
Metastases, n (%)
3 (16.7)
80 (32.8)
0.195
0.186
0.219
—
9.
Recurrence, n (%)
2 (10.5)
23 (9.4)
1 : 000
1.000
1.000
—
10.
Mean survival in months (n ± SE)
151 ± 14.9
192 ± 7
0.792
0.090
0.391
—
aAll values obtained on univariate analysis. b PDA, poorly differentiated areas. Significant positive correlation of HER-2 expression and overall tumor size; FTC tumor size.
